[Skip to Navigation]
Health Care Policy and Law
March 2, 2020

Integrated Drug Reviews at the US Food and Drug Administration—Legal Concerns and Knowledge Lost

Author Affiliations
  • 1Health Law Institute, Schulich School of Law, Dalhousie University, Halifax, Nova Scotia, Canada
  • 2Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
  • 3Engelberg Center on Innovation Law & Policy, New York University School of Law, New York
  • 4Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore
JAMA Intern Med. 2020;180(5):629-630. doi:10.1001/jamainternmed.2020.0074

When the US Food and Drug Administration (FDA) approves a new drug, federal law requires public disclosure of the review documents prepared by scientific disciplines (eg, clinical, toxicology, statistical) during the review.1 These scientific reviews are published on the FDA Drugs@FDA website (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm). In many cases, the data and analyses contained in those reviews have proved useful to public health.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words